<DOC>
	<DOCNO>NCT00352742</DOCNO>
	<brief_summary>The purpose study describe safety effect ATN-224 combination bortezomib ( Velcade® ) patient Multiple Myeloma relapse refractory bortezomib .</brief_summary>
	<brief_title>A Study ATN-224 Bortezomib Patients With Multiple Myeloma</brief_title>
	<detailed_description>Multiple myeloma bone marrow base malignancy plasma cell highly treatable rarely curable . Angiogenesis , define growth new blood vessel pre-existing vessel , requirement growth nearly tumor . An increase bone marrow angiogenesis present Multiple Myeloma correlate disease progression . Several new therapy target angiogenic pathway show clinical efficacy . ATN-224 small molecule show pre-clinical study antiangiogenic . Using one agent overcome resistance another agent treatment regimen use oncology . A preclinical study combination ATN-224 bortezomib show combination effective either single agent bortezomib resistant cell line .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Tetrathiomolybdate</mesh_term>
	<mesh_term>Bortezomib</mesh_term>
	<mesh_term>Molybdenum</mesh_term>
	<criteria>1 . Histologically cytologically confirm multiple myeloma treat least one different prior antimyeloma regimen include one bortezomib currently show evidence progressive disease 2 . Myeloma refractory recent bortezomibcontaining regimen demonstrate progressive disease bortezomib relapse within 12 week last dose bortezomib either single agent combination agent 3 . Measurable disease define serum Mprotein concentration electrophoresis ≥1 g/dL IgG myeloma ≥0.5 g/dL IgA myeloma IgM myeloma urinary excretion monoclonal light chain ≥200 mg/24 hour 4 . Age &gt; 18 year 5 . Life expectancy great 3 month 6 . ECOG performance status &lt; 2 ( Karnofsky &gt; 60 % ; see Appendix A ) 7 . Adequate organ marrow function define : absolute neutrophil count ≥1,000/uL platelets ≥75,000/uL hemoglobin ≥8 g/dL total bilirubin ≤2 X institutional upper limit normal ( ULN ) AST ( SGOT ) ALT ( SGPT ) ≤3 X ULN creatinine clearance ≥30 mL/min ( measure calculate ) Patients allow receive blood transfusion receive first dose ATN224 bring hemoglobin level ≥8 g/dL meet eligibility criterion . 8 . Use adequate contraception . The effect ATN 224 develop human fetus recommend therapeutic dose unknown . For reason antiangiogenic agent know teratogenic , woman childbearing potential men partner childbearing potential must agree use adequate contraception ( hormonal and/or barrier method birth control ; abstinence ) prior study entry duration study participation follow visit 28 day last dose ATN 224 . 9 . Willingness forego take copper zinccontaining vitamins supplement 10 . Ability understand willingness sign write informed consent document . 1 . Chemotherapy radiotherapy within 4 week ( 6 week nitrosoureas mitomycin C ) thalidomide , lenalidomide , dexamethasone , arsenic trioxide , bortezomib , glucocorticosteroids within 3 week prior first dose ATN224 failure recover reversible adverse event due agent administer previously 2 . Patients tolerate , base previous experience , assign dose bortezomib , include ≥ Grade 2 neuropathy 3 . Concurrent administration investigational agent 4 . History malabsorption syndromes gastrointestinal disorder may affect ATN224 absorption , include bowel obstruction , celiac disease , sprue , cystic fibrosis 5 . Ineligible receive omeprazole ( Prilosec® OTC ) longacting antacid 6 . Inability swallow study medication capsule 7 . Not suitable candidate opinion investigator additional bortezomib therapy 8 . Other serious medical psychiatric illness prevent informed consent intensive treatment 9 . Uncontrolled intercurrent illness include , limited , ongoing active infection , symptomatic congestive heart failure , unstable angina pectoris , cardiac arrhythmia , psychiatric illness/social situation would limit compliance study requirement 10 . Women pregnant lactate 11 . Known history HIV 12 . History another prior cancer , except basal cell carcinoma carcinoma situ cervix ( evidence recurrence least 5 year )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2008</verification_date>
	<keyword>Multiple myeloma</keyword>
	<keyword>bortezomib</keyword>
	<keyword>ATN-224</keyword>
	<keyword>refractory</keyword>
	<keyword>relapse</keyword>
	<keyword>antiangiogenic</keyword>
</DOC>